Non Alcoholic Fatty Liver Disease (NAFLD) Global Clinical ... · Non Alcoholic Fatty Liver Disease...
12
Non Alcoholic Fatty Liver Disease (NAFLD) Global Clinical Trials Review, H1, 2015 GDHC2542CTIDB / Published JAN 2015 © GlobalData. This report is a licensed product and is not to be photocopied Page 1 Non Alcoholic Fatty Liver Disease (NAFLD) Global Clinical Trials Review, H1, 2015 Reference Code: GDHC2542CTIDB Publication Date: JAN 2015 SAMPLE
Transcript of Non Alcoholic Fatty Liver Disease (NAFLD) Global Clinical ... · Non Alcoholic Fatty Liver Disease...
Non Alcoholic Fatty Liver Disease (NAFLD) Global Clinical Trials Review, H1, 2015
GDHC2542CTIDB / Published JAN 2015
© GlobalData. This report is a licensed product and is not to be photocopied
Page 1
Non Alcoholic Fatty Liver Disease (NAFLD)
Global Clinical Trials Review, H1, 2015
Reference Code: GDHC2542CTIDB
Publication Date: JAN 2015
SAMPLE
Non Alcoholic Fatty Liver Disease (NAFLD) Global Clinical Trials Review, H1, 2015
GDHC2542CTIDB / Published JAN 2015
© GlobalData. This report is a licensed product and is not to be photocopied
Page 2
Table of Contents
Table of Contents ............................................................................................................................................................................... 2
List of Tables .................................................................................................................................................................................. 4
List of Figures ................................................................................................................................................................................. 5
Introduction ......................................................................................................................................................................................... 6
Non Alcoholic Fatty Liver Disease (NAFLD) ................................................................................................................................... 6
Report Guidance ............................................................................................................................................................................. 6
Clinical Trials by Region ..................................................................................................................................................................... 7
Clinical Trials and Average Enrollment by Country ......................................................................................................................... 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific .............................................................................................. 10
Top Five Countries Contributing to Clinical Trials in Europe ..................................................................................................... 11
Top Countries Contributing to Clinical Trials in North America .................................................................................................. 12
Top Countries Contributing to Clinical Trials in Middle East and Africa ..................................................................................... 13
Top Countries Contributing to Clinical Trials in Central and South America.............................................................................. 14
Clinical Trials by G7 Countries: Proportion of Non Alcoholic Fatty Liver Disease (NAFLD) to Gastrointestinal Clinical Trials ......... 15
Clinical Trials by Phase in G7 Countries .......................................................................................................................................... 16
Clinical Trials in G7 Countries by Trial Status .................................................................................................................................. 17
Clinical Trials by E7 Countries: Proportion of Non Alcoholic Fatty Liver Disease (NAFLD) to Gastrointestinal Clinical Trials .......... 18
Clinical Trials by Phase in E7 Countries ........................................................................................................................................... 19
Clinical Trials in E7 Countries by Trial Status ................................................................................................................................... 20
Clinical Trials by Phase .................................................................................................................................................................... 21
In Progress Trials by Phase .......................................................................................................................................................... 22
Clinical Trials by Trial Status ............................................................................................................................................................ 23
Clinical Trials by End Point Status .................................................................................................................................................... 24
Unaccomplished Trials of Non Alcoholic Fatty Liver Disease (NAFLD) ............................................................................................ 25
Subjects Recruited Over a Period of Time ....................................................................................................................................... 27
Clinical Trials by Sponsor Type ........................................................................................................................................................ 28
Prominent Sponsors ......................................................................................................................................................................... 29
Top Companies Participating in Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials ................................... 30
Prominent Drugs .............................................................................................................................................................................. 31
Clinical Trial Profiles ......................................................................................................................................................................... 32
Clinical Trial Overview of Top Companies .................................................................................................................................... 32
Galmed International Ltd. .......................................................................................................................................................... 32
Clinical Trial Overview of Galmed International Ltd. .................................................................................................................. 32
AstraZeneca PLC ...................................................................................................................................................................... 33
Clinical Trial Overview of AstraZeneca PLC .............................................................................................................................. 33
TCM Biotech International Corp ................................................................................................................................................ 34
Clinical Trial Overview of TCM Biotech International Corp ........................................................................................................ 34
Phenex Pharmaceuticals AG .................................................................................................................................................... 35
Clinical Trial Overview of Phenex Pharmaceuticals AG ............................................................................................................ 35
PharmaKing Co., Ltd. ................................................................................................................................................................ 36
Clinical Trial Overview of PharmaKing Co., Ltd. ........................................................................................................................ 36
Genextra S.p.a. ......................................................................................................................................................................... 37
Clinical Trial Overview of Genextra S.p.a. ................................................................................................................................. 37
F. Hoffmann-La Roche Ltd. ....................................................................................................................................................... 38
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. ............................................................................................................... 38
SAMPLE
Non Alcoholic Fatty Liver Disease (NAFLD) Global Clinical Trials Review, H1, 2015
GDHC2542CTIDB / Published JAN 2015
© GlobalData. This report is a licensed product and is not to be photocopied
Page 3
Barij essence Company ............................................................................................................................................................ 39
Clinical Trial Overview of Barij essence Company .................................................................................................................... 39
Antipodean Pharmaceuticals, Inc. ............................................................................................................................................. 40
Clinical Trial Overview of Antipodean Pharmaceuticals, Inc. ..................................................................................................... 40
Abbott Laboratories ................................................................................................................................................................... 41
Clinical Trial Overview of Abbott Laboratories ........................................................................................................................... 41
Clinical Trial Overview of Top Institutes / Government ................................................................................................................. 42
Tabriz University of Medical Sciences ....................................................................................................................................... 42
Clinical Trial Overview of Tabriz University of Medical Sciences .............................................................................................. 42
Third Military Medical University ................................................................................................................................................ 43
Clinical Trial Overview of Third Military Medical University ....................................................................................................... 43
Tehran University of Medical Sciences ..................................................................................................................................... 44
Clinical Trial Overview of Tehran University of Medical Sciences ............................................................................................. 44
University of Michigan ............................................................................................................................................................... 45
Clinical Trial Overview of University of Michigan ....................................................................................................................... 45
The National Institute of Diabetes and Digestive and Kidney Diseases .................................................................................... 46
Clinical Trial Overview of The National Institute of Diabetes and Digestive and Kidney Diseases ............................................ 46
FUDAN University ..................................................................................................................................................................... 47
Clinical Trial Overview of FUDAN University ............................................................................................................................. 47
Massachusetts General Hospital ............................................................................................................................................... 48
Clinical Trial Overview of Massachusetts General Hospital ...................................................................................................... 48
Chinese University of Hong Kong.............................................................................................................................................. 49
Clinical Trial Overview of Chinese University of Hong Kong ..................................................................................................... 49
Ahvaz Jundishapur University of Medical Sciences .................................................................................................................. 50
Clinical Trial Overview of Ahvaz Jundishapur University of Medical Sciences .......................................................................... 50
Bambino Gesu Hospital and Research Institute ........................................................................................................................ 51
Clinical Trial Overview of Bambino Gesu Hospital and Research Institute ................................................................................ 51
Five Key Clinical Profiles .................................................................................................................................................................. 52
Appendix .......................................................................................................................................................................................... 80
Abbreviations ................................................................................................................................................................................ 80
Definitions ..................................................................................................................................................................................... 80
Research Methodology ................................................................................................................................................................. 81
Secondary Research .................................................................................................................................................................... 81
About GlobalData ......................................................................................................................................................................... 82
Disclaimer ..................................................................................................................................................................................... 82
Source .......................................................................................................................................................................................... 82
SAMPLE
Non Alcoholic Fatty Liver Disease (NAFLD) Global Clinical Trials Review, H1, 2015
GDHC2542CTIDB / Published JAN 2015
© GlobalData. This report is a licensed product and is not to be photocopied
Page 4
List of Tables
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials by Region, 2015* ................................................. 7
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015*8
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* ................... 9
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2015* ......................... 10
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* ................................ 11
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, North America, Top Countries, 2015* ............................ 12
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2015* ............... 13
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Central and South America, Top Countries, 2015* ........ 14
Proportion of Non Alcoholic Fatty Liver Disease (NAFLD) to Gastrointestinal Clinical Trials, G7 Countries (%), 2015* .................. 15
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* ...................................... 16
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* .............................. 17
Proportion of Non Alcoholic Fatty Liver Disease (NAFLD) to Gastrointestinal Clinical Trials, E7 Countries (%), 2015* ................... 18
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* ...................................... 19
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* .............................. 20
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials by Phase, 2015* ................................................ 21
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials In Progress by Phase 2015* .............................. 22
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials by Trial Status, 2015* ........................................ 23
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, by End Point Status, 2015* ................................ 24
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Withdrawn Clinical Trials, 2015* .............................................. 25
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Terminated Clinical Trials, 2015* ............................................. 26
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 . 27
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* ........................ 28
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, Key Sponsors, 2015* ......................................... 29
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* ...................... 30
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015*
......................................................................................................................................................................................................... 31
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by Galmed International
Ltd., 2015* ........................................................................................................................................................................................ 32
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2015*
......................................................................................................................................................................................................... 33
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by TCM Biotech
International Corp, 2015*.................................................................................................................................................................. 34
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by Phenex Pharmaceuticals
AG, 2015* ......................................................................................................................................................................................... 35
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by PharmaKing Co., Ltd.,
2015* ................................................................................................................................................................................................ 36
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by Genextra S.p.a., 2015* 37
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche
Ltd., 2015* ........................................................................................................................................................................................ 38
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by Barij essence Company,
2015* ................................................................................................................................................................................................ 39
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by Antipodean
Pharmaceuticals, Inc., 2015* ............................................................................................................................................................ 40
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by Abbott Laboratories,
2015* ................................................................................................................................................................................................ 41
SAMPLE
Non Alcoholic Fatty Liver Disease (NAFLD) Global Clinical Trials Review, H1, 2015
GDHC2542CTIDB / Published JAN 2015
© GlobalData. This report is a licensed product and is not to be photocopied
Page 5
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by Tabriz University of
Medical Sciences, 2015* .................................................................................................................................................................. 42
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by Third Military Medical
University, 2015* .............................................................................................................................................................................. 43
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by Tehran University of
Medical Sciences, 2015* .................................................................................................................................................................. 44
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Michigan,
2015* ................................................................................................................................................................................................ 45
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by The National Institute of
Diabetes and Digestive and Kidney Diseases, 2015* ....................................................................................................................... 46
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by FUDAN University, 2015*
......................................................................................................................................................................................................... 47
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by Massachusetts General
Hospital, 2015* ................................................................................................................................................................................. 48
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by Chinese University of
Hong Kong, 2015* ............................................................................................................................................................................ 49
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by Ahvaz Jundishapur
University of Medical Sciences, 2015* ............................................................................................................................................. 50
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by Bambino Gesu Hospital
and Research Institute, 2015* .......................................................................................................................................................... 51
List of Figures
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials by Region (%), 2015* ........................................... 7
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015*8
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* ................... 9
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2015* .................. 10
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015* ......................... 11
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, North America, Top Countries (%), 2015* ...................... 12
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2015* ......... 13
Proportion of Non Alcoholic Fatty Liver Disease (NAFLD) to Gastrointestinal Clinical Trials, G7 Countries (%), 2015* .................. 15
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* ...................................... 16
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* .............................. 17
Proportion of Non Alcoholic Fatty Liver Disease (NAFLD) to Gastrointestinal Clinical Trials, E7 Countries (%), 2015* ................... 18
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* ...................................... 19
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* .............................. 20
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials by Phase (%), 2015* .......................................... 21
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* ............................. 22
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials by Trial Status, 2015* ........................................ 23
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, by End Point Status, 2015* ............................... 24
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 . 27
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* .................. 28
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, Key Sponsors, 2015* ........................................ 29
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* ..................... 30
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs,
2015* ................................................................................................................................................................................................ 31
GlobalData Methodology .................................................................................................................................................................. 81
SAMPLE
Non Alcoholic Fatty Liver Disease (NAFLD) Global Clinical Trials Review, H1, 2015
GDHC2542CTIDB / Published JAN 2015
© GlobalData. This report is a licensed product and is not to be photocopied
Page 6
Introduction
Non Alcoholic Fatty Liver Disease (NAFLD)
Nonalcoholic fatty liver disease is a term used to describe the accumulation of fat in the liver of people who drink little or no alcohol. Nonalcoholic fatty liver disease is common and, for most people, causes no signs and symptoms and no complications. But in some people with nonalcoholic fatty liver disease, the fat that accumulates can cause inflammation and scarring in the liver. This more serious form of nonalcoholic fatty liver disease is sometimes called nonalcoholic steatohepatitis. At its most severe, nonalcoholic fatty liver disease can progress to liver failure.
Report Guidance
Non Alcoholic Fatty Liver Disease (NAFLD) Global Clinical Trials Review, H1, 2015 outlines clinical trials in Non
Alcoholic Fatty Liver Disease (NAFLD). The prominent features of this report are -
1. Comprehensive data related to Non Alcoholic Fatty Liver Disease (NAFLD) clinical trials by region, country,
phase, and recruitment status
2. Clinical trials conducted by key Companies and Institutes. The selection of the sponsors is based on the total
number of Non Alcoholic Fatty Liver Disease (NAFLD) clinical trials conducted
3. Prominent drugs are provided based on number of ongoing clinical trials
4. The trials compiled in this report are from clinical trial registries, conferences, journals etc
SAMPLE
Non Alcoholic Fatty Liver Disease (NAFLD) Global Clinical Trials Review, H1, 2015
GDHC2542CTIDB / Published JAN 2015
© GlobalData. This report is a licensed product and is not to be photocopied
Page 7
Clinical Trials by Region
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials by Region (%), 2015*
Source: GlobalData’s Pharma eTrack Clinical Trials Database
(*)Trials are taken for a time period of 1995 - 2015
2015 trials are taken as of January 2015
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials by Region, 2015*
World Zones Number of Clinical Trials
Asia-Pacific
North America
Middle East and Africa
Europe
South and Central America
Locations Not Specified
Total
Source: GlobalData’s Pharma eTrack Clinical Trials Database
(*)Trials are taken for a time period of 1995 - 2015
2015 trials are taken as of January 2015 SAMPLE
Non Alcoholic Fatty Liver Disease (NAFLD) Global Clinical Trials Review, H1, 2015
GDHC2542CTIDB / Published JAN 2015
© GlobalData. This report is a licensed product and is not to be photocopied
Page 9
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015*
Source: GlobalData’s Pharma eTrack Clinical Trials Database
(*)Trials are taken for a time period of 1995 - 2015
2015 trials are taken as of January 2015
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015*
Country Name Number of Clinical Trials (In Progress)
United States
Iran
China
Japan
Austria
Canada
Italy
United Kingdom
Germany
Denmark
Total
Source: GlobalData’s Pharma eTrack Clinical Trials Database
(*)Trials are taken for a time period of 1995 - 2015
2015 trials are taken as of January 2015
SAMPLE
Non Alcoholic Fatty Liver Disease (NAFLD) Global Clinical Trials Review, H1, 2015
GDHC2542CTIDB / Published JAN 2015
© GlobalData. This report is a licensed product and is not to be photocopied
Page 10
Top Five Countries Contributing to Clinical Trials in Asia-Pacific
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2015*
Source: GlobalData’s Pharma eTrack Clinical Trials Database
(*)Trials are taken for a time period of 1995 - 2015
2015 trials are taken as of January 2015
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2015*
Country Name Number of Clinical Trials
Japan
China
South Korea
India
Australia
Total
Source: GlobalData’s Pharma eTrack Clinical Trials Database
(*)Trials are taken for a time period of 1995 - 2015
2015 trials are taken as of January 2015 SAMPLE
Non Alcoholic Fatty Liver Disease (NAFLD) Global Clinical Trials Review, H1, 2015
GDHC2542CTIDB / Published JAN 2015
© GlobalData. This report is a licensed product and is not to be photocopied
Page 80
Appendix
Abbreviations
BRIC: Brazil, Russia, India and China
Definitions
PHASE I TRIALS: Initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the
side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy
participants and/or patients.
PHASE II TRIALS: Controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular
indication or indications in patients with the disease or condition under study and to determine the common short-term
side effects and risks.
PHASE III TRIALS: Expanded controlled and uncontrolled trials after preliminary evidence suggesting effectiveness
of the drug has been obtained, and were intended to gather additional information to evaluate the overall benefit-risk
relationship of the drug and provide an adequate basis for physician labeling.
PHASE IV TRIALS: Post-marketing studies to delineate additional information including the drug's risks, benefits,
and optimal use.
TRIAL STATUS: Indicates the current stage of a trial, whether it is planned, ongoing, or completed. Possible values
include:
Trial in Progress: This is inclusive of;
Planned: participants were not yet being recruited or enrolled
Recruiting: participants were currently being recruited and enrolled
Enrolling by invitation: participants were being (or will be) selected from a predetermined population
Active, not recruiting: study is ongoing (i.e., patients were being treated or examined), but enrollment has
completed
Completed: the study has concluded normally; participants were no longer being examined or treated (i.e.,
last patient's last visit has occurred)
Suspended: recruiting or enrolling participants has halted prematurely but potentially will resume
Terminated: recruiting or enrolling participants has halted prematurely and will not resume; participants were
no longer being examined or treated
Withdrawn: study halted prematurely, prior to enrollment of first participant
SUBJECTS RECRUITED: The number of patients so enrolled for the trial in concern, to be analyzed.
UNACCOMPLISHED TRIALS: The category comprising of the terminated, withdrawn and suspended trials.
SAMPLE
Non Alcoholic Fatty Liver Disease (NAFLD) Global Clinical Trials Review, H1, 2015
GDHC2542CTIDB / Published JAN 2015
© GlobalData. This report is a licensed product and is not to be photocopied
Page 81
Research Methodology
GlobalData dedicated Research and Analysis Teams consists of experienced professionals with a pedigree in
marketing, market research and consulting in the pharmaceutical industry with advanced statistical expertise.
GlobalData adheres to the Codes of Practice of the Market Research Society (www.mrs.org.uk) and the Society of
Competitive Intelligence Professionals (www.scip.org).
All GlobalData databases were continuously updated and revised. The following research methodology is followed for
all databases and reports.
GlobalData Methodology
Data extraction from Pharma eTrack
Data Analysis
Self QC
Quality check by QC Lead
Submission of the Report
Data Validation
Source: GlobalData
Secondary Research
The research process begins with exhaustive secondary research on internal and external sources being carried out
to source qualitative and quantitative information relating to each market.
The secondary research sources that were typically referred to include, but were not limited to:
Company websites, annual reports, financial reports, broker reports, investor presentations and SEC Filings;
Industry trade journals, scientific journals and other technical literature;
Internal and external proprietary databases;
Relevant patent and regulatory databases;
SAMPLE
Non Alcoholic Fatty Liver Disease (NAFLD) Global Clinical Trials Review, H1, 2015
GDHC2542CTIDB / Published JAN 2015
© GlobalData. This report is a licensed product and is not to be photocopied
Page 82
National government documents, statistical databases and market reports;
Procedure registries; and
News articles, press releases and web-casts specific to the companies operating in the market.
About GlobalData
We hope that the data and analysis in this brief will help you make informed and imaginative business decisions. If
you have further requirements, GlobalData consulting team may be able to help you. GlobalData offers Tailor made
analytical and advisory services to drive your key strategic decisions.
Disclaimer
All Rights Reserved.
No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form by any means,
electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publisher,
GlobalData.
Source
http://clinicaltrials.gov/
http://www.pharmaetrack.com/
https://www.goldbamboo.com/pictures-t1192.html
http://www.trialscentral.org/
http://www.thefreelibrary.com/
http://dailymed.nlm.nih.gov/dailymed/about.cfm
http://www.controlled-trials.com/isrctn/search.html
http://www.anzctr.org.au/trialSearch.aspx
https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=search&action=input&language=E
SAMPLE
